About Alphina Therapeutics
Alphina Therapeutics is a private company based in New Haven, Connecticut. It has reported $17,005,305 raised in two offerings on Form D since September 2021. Its chief executive is Nicholas Galli.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Feb 23, 2026 | Mar 16, 2026 | $153,715of $10.0M target | 3 | $51,238 | Options, Simple Agreements for Future Equity (SAFEs)Rule 506(b) | Form D ↗ |
| Sep 7, 2021 | Sep 15, 2021 | $16,851,590of $39.9M target | 19 | $886K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $17,005,305 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Alphina Therapeutics's Form D filed Mar 16, 2026.
Earlier filings also listed Stanley Choy (executive officer, last listed Sep 2021) and Anurag Agarwal (director, last listed Sep 2021).